Navigation Links
One-Year Data Show Golimumab Improved Signs and Symptoms In Patients with Psoriatic Arthritis In Phase 3 Study
Date:10/27/2008

regulatory approval, among other uncertainties. For further details about these and other factors that may impact the forward-looking statements, see Schering-Plough's Securities and Exchange Commission filings, including Item 8.01 of Schering-Plough's Form 8-K filed October 21, 2008.


'/>"/>
SOURCE Centocor
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. Phase 3 studies show golimumab significantly improved signs and symptoms of rheumatoid arthritis
2. Medarex Receives Milestone Payment for Submission of Regulatory Application Requesting Approval of Golimumab (CNTO 148) in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
3. Centocor, Inc. and Schering-Plough Submit Application Requesting Approval of Golimumab in Europe for the Treatment of Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis
4. In-Room Computers and Wall-Mounted Proximity Systems Computer WorkStations Deliver Increased Efficiency; Improved Patient Care
5. Finesse Solutions Launches Improved E-Store for Sensors and Transmitters
6. Kelly Osbourne and International Health Groups Call for Improved Education on Choices and Usage of Contraception
7. Enobia Pharma Presents PreClinical Data Showing ENB-0040 Significantly Improved Survival and Healed Skeletal Manifestations of Severe Hypophosphatasia in Mice
8. Improved culture system for hepatitis C virus infection
9. Pharmacy Students Taught Improved Medication Adherence and Holistic Health Services Through Program Incorporating InforMedixs Med-eXpert(TM) System
10. Sensitivity Enhancements to Monograms Trofile(TM) Assay Demonstrate Improved Power to Select Patients for CCR5 Antagonist Therapy
11. China Kangtai Cactus Biotech Announces Improved Milk Production in Cows From Companys Cactus Cattle Feed
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... (PRWEB) July 25, 2014 According to ... "Biological Drugs Market - Global Industry Analysis, Size, Share, ... biological drugs market is estimated at USD 161,056.5 million ... CAGR of 10.1% from 2014 to 2020, to reach ... , The biological drugs market is witnessing a significant ...
(Date:7/25/2014)... , July 25, 2014  Galmed Pharmaceuticals Ltd. (Nasdaq: ... focused on the development and commercialization of a once-daily, ... cholesterol gallstones, today announced financial results for the period ... Financial Summary: , Reported cash and cash equivalents ... $137,000 at December 31, 2013.  , Reported a ...
(Date:7/24/2014)... 2014 -- Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced ... control Phase 3 study of Zerenex (ferric citrate), the ... treatment of hyperphosphatemia in patients with end-stage renal disease ... iRon delivery with FErric CiTrate in EsrD) was published ... Society of Nephrology ( JASN ). ...
(Date:7/24/2014)... Calif. , July 24, 2014  Asterias ... in the emerging field of regenerative medicine, announced ... of a presentation to investors on Tuesday, July ... PDT.  The presentation will include an overview of ... access the webcast, visit http://www.ustream.tv/channel/asterias-biotherapeutics at ...
Breaking Biology Technology:Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 2Biological Drugs Market: Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2014 - 2020 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 2Galmed Pharmaceuticals Reports First Half 2014 Financial Results 3Galmed Pharmaceuticals Reports First Half 2014 Financial Results 4Galmed Pharmaceuticals Reports First Half 2014 Financial Results 5Galmed Pharmaceuticals Reports First Half 2014 Financial Results 6Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Asterias Biotherapeutics Announces Live Investor Webcast 2Asterias Biotherapeutics Announces Live Investor Webcast 3Asterias Biotherapeutics Announces Live Investor Webcast 4
... ... ... Paul LaViolette to retire from Company, NATICK, Mass., ... Jim Tobin will be extending his tenure at the Company. The Company,said Tobin plans to remain ...
... Calif., June 3 Masimo Corporation,(Nasdaq: MASI ... oximetry, today announced,that it is scheduled to present ... at The Ritz Carlton, Laguna Nigel, in Dana ... p.m. PT. Joe E. Kiani, Chairman and,CEO, will ...
... ANGELES, June 3 Growing Generations, the nation,s,largest surrogacy ... egg donation services to men with HIV and allows ... The new program is made possible due to ... as well as the implementation of recent California,legislation enacted ...
Cached Biology Technology:Boston Scientific Announces CEO Jim Tobin to Extend Tenure 2Boston Scientific Announces CEO Jim Tobin to Extend Tenure 3Boston Scientific Announces CEO Jim Tobin to Extend Tenure 4Boston Scientific Announces CEO Jim Tobin to Extend Tenure 5Masimo to Present at Goldman Sachs 29th Annual Global Healthcare Conference 2Growing Generations Announces Surrogacy Program for Men with HIV 2
(Date:7/25/2014)... Nearly 600 scientists from 25 countries and ... Meeting organized by the Genetics Society of America ... in Seattle. The conference will feature close to ... results on topics including gene expression and regulation, ... technologies, evolution, aging, and a variety of diseases. ...
(Date:7/25/2014)... pleiotropic factor characterized by the existence of numerous ... confer to the protein deeply different characteristics. NRG1 ... occurring during development and the different phases occurring ... axon regrowth, remyelination and target reinnervation, Researchers at ... the soluble NRG1 upregulation observed in Schwann cells ...
(Date:7/25/2014)... Institute for Medical Research have identified the functions ... crucial to triggering the mating process in mice. , ... mouse detect pheromones that indicate when a female is ... if the female mouse is ovulating and ready to ... mating. Stowers, researchers believe mice developed this system through ...
Breaking Biology News(10 mins):Yeast meeting to showcase latest breakthroughs in genetics and molecular biology 2It takes two to court 2It takes two to court 3
... new cases of the genetic disease Noonan Syndrome are so ... normal father,s production of sperm carrying the disease trait. ... sperm stem cell it makes that cell more likely to ... then is more likely to have an affected child because ...
... average 5-year survival for colorectal cancer (CRC) is less ... if detected early. A new non-invasive test has been ... tissues and blood sera. This test detected 87% of ... difference between early and advanced stages, while correctly identifying ...
... must minimize the humanness of their enemies in order to ... by feelings of empathy for opponents. But indifference to the ... provide troops with a better path back to healthy civilian ... hypothesis is based on new work showing how the brain ...
Cached Biology News:Biomarker identification may lead to new noninvasive test for colorectal cancer detection 2A way of thinking may enable battle but prevent war crimes 2A way of thinking may enable battle but prevent war crimes 3A way of thinking may enable battle but prevent war crimes 4A way of thinking may enable battle but prevent war crimes 5A way of thinking may enable battle but prevent war crimes 6
... cycler with 96 x 0.2 ml reaction ... (PCR) applications. It is equipped with an ... that is compatible with optical modules for ... control by algorithm, block, or in-sample probe. ...
... compact benchtop and stackable multi-function incubator. ... a large display screen to accurately ... circulation inside to evenly distribute temperature ... easily calibrated from the microprocessor controller. ...
...
Tan solid. A glycoside used to permeabilize cellular membranes. Exhibits hemolytic activity. Contaminants: ash: ≤10%. Soluble in H 2 O. pH 4.4 - 4.6. RTECS VQ1400000, CAS 8047-15-2. References:...
Biology Products: